Literature DB >> 15940255

The 'regulatory' beta-subunit of protein kinase CK2 negatively influences p53-mediated allosteric effects on Chk2 activation.

Marina Bjørling-Poulsen1, Simone Siehler, Lisa Wiesmüller, David Meek, Karsten Niefind, Olaf-Georg Issinger.   

Abstract

The 'regulatory' beta-subunit of protein kinase CK2 has previously been shown to interact with protein kinases such as A-Raf, c-Mos, Lyn and Chk1 in addition to the catalytic subunit of CK2. Sequence alignments suggest that these interactions have a structural basis, and hence other protein kinases harboring corresponding sequences may be potential interaction partners for CK2beta. We show here that Chk2 specifically interacts with CK2beta in vitro and in cultured cells, and that activation of Chk2 leads to a reduction of this interaction. Additionally, we show that the presence of the CK2beta-subunit significantly reduces the Chk2-catalysed phosphorylation of p53 in vitro. These findings support the notion that CK2beta can act as a general modulator of remote docking sites in protein kinase--substrate interactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940255     DOI: 10.1038/sj.onc.1208762

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling.

Authors:  Nam Y Lee; John C Haney; Julie Sogani; Gerard C Blobe
Journal:  FASEB J       Date:  2009-07-10       Impact factor: 5.191

2.  Ability of CK2beta to selectively regulate cellular protein kinases.

Authors:  Birgitte B Olsen; Barbara Guerra
Journal:  Mol Cell Biochem       Date:  2008-06-17       Impact factor: 3.396

3.  Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.

Authors:  Dan Zhu; Jennifer Hensel; Robert Hilgraf; Mahan Abbasian; Owen Pornillos; Gordafaried Deyanat-Yazdi; Xuequn Helen Hua; Sarah Cox
Journal:  Mol Cell Biochem       Date:  2009-07-21       Impact factor: 3.396

Review 4.  Targeting protein kinase CK2 in the treatment of cholangiocarcinoma.

Authors:  Padma-Sheela Jayaraman; Kevin Gaston
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

5.  Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Authors:  Sabrina Manni; Alessandra Brancalion; Elisa Mandato; Laura Quotti Tubi; Anna Colpo; Marco Pizzi; Rocco Cappellesso; Fortunato Zaffino; Speranza Antonia Di Maggio; Anna Cabrelle; Filippo Marino; Renato Zambello; Livio Trentin; Fausto Adami; Carmela Gurrieri; Gianpietro Semenzato; Francesco Piazza
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

6.  Ablation of beta subunit of protein kinase CK2 in mouse oocytes causes follicle atresia and premature ovarian failure.

Authors:  Qiu-Xia Liang; Zhen-Bo Wang; Fei Lin; Chun-Hui Zhang; Hong-Mei Sun; Liang Zhou; Qian Zhou; Heide Schatten; Filhol-Cochet Odile; Boldyreff Brigitte; Qing-Yuan Sun; Wei-Ping Qian
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.